. 2022 Feb 16;11(1):15. doi: 10.3390/antib11010015

Table 3.

CD20+ %, PD-L1+CD20+ %, and PD-1+CD20+ % in DLBCL patients and healthy subjects.

		Controls (I)	Pre-Therapy DLBCL (II)	Post-Therapy DLBCL (III)	p
		N = 19	N = 20	N = 20	I vs. II	I vs. III	II vs. III
CD20+ %	Median	24	22	10	0.525	<0.001 *	<0.001 **
CD20+ %	IQR	(20–25)	(18.3–26.8)	(9.6–11.8)	0.525	<0.001 *	<0.001 **
PDL-1+CD20+ %	Median	1	16	6.8	<0.001 **	<0.001 *	<0.001 **
PDL-1+CD20+ %	IQR	(0.8–1)	(15–23)	(6–7.9)	<0.001 **	<0.001 *	<0.001 **
PD-1+CD20+ %	Median	0.7	9	0.9	<0.001 **	0.575	<0.001 **
PD-1+CD20+ %	IQR	(0.6–1)	(8–11)	(0.6–1)	<0.001 **	0.575	<0.001 **

Group I: Healthy volunteers; Group II: Pre-therapy DLBCL patients; Group III: Patients completed 6 CHOP cycles. N: Number; IQR: Interquartile range. Kruskal Wallis test was used for the analysis of data between the three groups followed by pairwise comparisons between every two groups using Bonferroni correction. Significant differences are identified with asterisks (*). High significant differences are identified by an asterisk (**) (p < 0.001).